CAESAREA, Israel, May 4, 2017 /PRNewswire/ -- DarioHealth
Corp. (NASDAQ: DRIO), a leading global digital health company with
mobile health and big data solutions, today announced that it is
teaming up with Auto Control Medical, an A&D Company, and STI
Technologies Limited to lower diabetes healthcare costs in
Canada, effective immediately.
Through STI's innoviCares card, which is available throughout all
provinces and territories in Canada, DarioHealth customers will be eligible
for additional savings when shopping for Dario supplies in local
pharmacies.
The innoviCares card is a free program that assists over 1.5
million Canadians to save money on selected prescriptions and
healthcare products. It works just like any insurance card and
covers a portion of the cost on many brand name products. Any
Canadian is eligible for the innoviCares program and there are no
eligibility requirements. DarioHealth worked with Auto Control
Medical, its exclusive Canadian partner, to secure this deal with
STI. Under the agreement, diabetes consumers will get up to
$10 off the cost of Dario™ Blood
Glucose Test Strips.
With DarioHealth's diabetes management systems, consumers are
enabled to track and monitor their blood glucose levels in a simple
manner, as the acclaimed Dario™ Blood Glucose Monitoring System
connects directly to ones' smartphone. This provides people with
diabetes an unrivaled method for self-diabetes management.
Erez Raphael, Chairman and CEO of
DarioHealth, commented on the announcement, "STI is more than a
prescription reimbursement plan; they support the healthcare system
in order to improve health outcomes for Canadian patients, and
DarioHealth is excited to collaborate with them and A&D on this
new initiative. We believe in giving consumers the best tools to
manage their treatment. In Canada
alone, there are 11 million people living with diabetes or
prediabetes, and DarioHealth is dedicated to provide them with
excellent treatment for their diabetes management."
Robert Burgy, General Manager of
Auto Control Medical, said in a joint statement with STI, "We are
pleased to announce the addition of Dario products to the
innoviCares card. Effective immediately, the innoviCare card will
provide financial assistance to customers seeking the Dario Blood
Glucose Test Strips when they present their card with a
prescription at their pharmacy. In addition to savings, we afford
customers smart options like setting refill reminders, which
ensures they never run out of the Dario test strips. 57% of people
with diabetes in Canada report
high out-of-pocket expenses and we believe this will alleviate some
of the cost."
DarioHealth is the creator of the all-in-one blood glucose meter
that is small enough to fit in one's pocket or purse. For more
information about this partnership visit:
https://www.innovicares.ca/en/dario.
About Auto Control Medical, an A&D Company
Auto Control Medical is a division of A&D Canada, Inc., a
subsidiary of A&D Company.
Auto Control Medical is one of the premier distributors of
hypertension, diabetes and respiratory products in Canada. Auto Control Medical has developed an
extensive customer network in its more than 17 years of service,
and distributes healthcare products through pharmacies, home care
stores and other channels throughout Canada.
Since 1977, A&D Medical has manufactured and distributed a
full line of advanced biometric monitoring solutions including
blood pressure monitors, weight scales, activity monitors, and
other health monitoring devices for consumer and professional use.
A&D Medical is the worldwide leader in connected health and
biometric measurement devices and services for consumer wellness
and chronic condition management, marketing under the A&D brand
globally and also the LifeSource brand in North America. A&D Medical is a division
of A&D Company, a global manufacturer of measurement equipment,
with operations in Asia,
Europe, Australia, Russia, North
America, and South
America.
About innoviCares
InnoviCares is Canada's largest
free prescription savings card, covering more than 100 brand-name
medications and healthcare products from 23 Canadian pharmaceutical
manufacturers.
The innoviCares card works like any drug insurance card at the
pharmacy, instantly paying a portion of the cost of participating
products. Funded by participating pharmaceutical manufacturers,
innoviCares is easy to use and available to all Canadians at no
cost.
InnoviCares delivers choice, is easy to use, and supports
Canadians to achieve better health outcomes. We're empowering
Canadians to take control of their health.
More information: https://www.innovicares.ca/en.
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company
serving tens of thousands of users with dynamic mobile health
solutions. We believe people deserve the best tools to manage their
treatment, and harnessing big data, we have developed a unique way
for our users to analyze and personalize their diabetes management.
With our smart diabetes solution, users have direct access to track
and monitor all facets of diabetes, without having the disease slow
them down. The acclaimed Dario™ Blood Glucose Monitoring System
all-in-one blood glucose meter and native smartphone app gives
users an unrivaled method for self-diabetes management. DarioHealth
is headquartered in Caesarea,
Israel with a regional office in Burlington, Massachusetts. For more
information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. Readers are cautioned that
certain important factors may affect the Company's actual results
and could cause such results to differ materially from any
forward-looking statements that may be made in this news release.
Factors that may affect the Company's results include, but are not
limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
shmuel@mydario.com
1-800-896-9062
DarioHealth Investor Relations Contact
Hayden IR
Rob Fink / Brett Maas
DRIO@HaydenIR.com
646-415-8972 / 646-536-7331
A&D Media Contact
Liz Kohler
lkohler@andonline.com
414-828-6198
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dariohealth-lowers-diabetes-healthcare-costs-in-canada-300451376.html
SOURCE DarioHealth Corp.